186 related articles for article (PubMed ID: 30679904)
1. YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway.
Tong H; Zhao K; Zhang J; Zhu J; Xiao J
Drug Des Devel Ther; 2019; 13():317-326. PubMed ID: 30679904
[TBL] [Abstract][Full Text] [Related]
2. UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma.
Zhou K; Wang D; Du X; Feng X; Zhu X; Wang C
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(6):916-926. PubMed ID: 38634120
[TBL] [Abstract][Full Text] [Related]
3. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
[No Abstract] [Full Text] [Related]
4. FOXN3 inhibits cell proliferation and invasion via modulating the AKT/MDM2/p53 axis in human glioma.
Wang C; Tu H; Yang L; Ma C; Hu J; Luo J; Wang H
Aging (Albany NY); 2021 Sep; 13(17):21587-21598. PubMed ID: 34511432
[TBL] [Abstract][Full Text] [Related]
5. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
[TBL] [Abstract][Full Text] [Related]
6. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
7. miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Chen Q; Wang W; Chen S; Chen X; Lin Y
Cell Mol Biol Lett; 2021 May; 26(1):21. PubMed ID: 34044759
[TBL] [Abstract][Full Text] [Related]
8. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
[No Abstract] [Full Text] [Related]
9. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
10. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
11. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
13. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
[TBL] [Abstract][Full Text] [Related]
14. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
15. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L
Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978
[TBL] [Abstract][Full Text] [Related]
16. MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Zhang X; Yu J; Zhao C; Ren H; Yuan Z; Zhang B; Zhuang J; Wang J; Feng B
Biomed Pharmacother; 2019 Jan; 109():2192-2202. PubMed ID: 30551476
[TBL] [Abstract][Full Text] [Related]
17. MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.
Sun YC; Wang J; Guo CC; Sai K; Wang J; Chen FR; Yang QY; Chen YS; Wang J; To TS; Zhang ZP; Mu YG; Chen ZP
BMC Cancer; 2014 Aug; 14():611. PubMed ID: 25151861
[TBL] [Abstract][Full Text] [Related]
18. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
[TBL] [Abstract][Full Text] [Related]
19. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
20. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
